Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 mg | $35 | In Stock | |
100 mg | $68 | In Stock | |
200 mg | $100 | In Stock | |
500 mg | $166 | In Stock | |
1 g | $245 | In Stock | |
1 mL x 10 mM (in DMSO) | $39 | In Stock |
Description | Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis. |
In vitro | Pivanex has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Pivanex (200 μM) causes enhancement in the G2-M phase, moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle. Pivanex (100-500 μM) shows significant anti-proliferation activity in K562 cells. Pivanex (100-500 μM) also increases apoptosis and caspase activity in K562 cells [1][2]. |
In vivo | Pivanex treatment also marked delays in the end stage of disease as defined by the onset of body mass loss. Pivanex (200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice [3]. |
Alias | Pivalyloxymethyl butyrate, AN-9 |
Molecular Weight | 202.25 |
Formula | C10H18O4 |
Cas No. | 122110-53-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (494.44 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.